Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
Mariane S Fontes,1,2 Daniel Vargas Pivato de Almeida,2,3 Clarissa Cavalin,1 Scott T Tagawa4 1Oncology Department, Oncoclinicas Group, Rio de Janeiro, Brazil; 2LACOG, Latin American Cooperative Oncology Group, Brazil; 3Oncology Department, Oncoclinicas Group, Porto Alegre, Brazil; 4Weill Cornell Medi...
Main Authors: | Fontes MS, Vargas Pivato de Almeida D, Cavalin C, Tagawa ST |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-12-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/targeted-therapy-for-locally-advanced-or-metastatic-urothelial-cancer--peer-reviewed-fulltext-article-OTT |
Similar Items
-
A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
by: Giuliana Pavone, et al.
Published: (2021-12-01) -
Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
by: Wensheng Liu, et al.
Published: (2023-11-01) -
Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus
by: Sascha Hoppe, et al.
Published: (2022-09-01) -
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
by: Mythili Shastry, et al.
Published: (2022-12-01) -
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
by: Pasquale Lombardi, et al.
Published: (2023-03-01)